Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
Conditions Studied
Interventions
- BIOLOGICAL PF-06835375
Study Locations (20)
Other
- Fakultni nemocnice Hradec Kralove — Hradec Králové
- Vseobecna fakultni nemocnice v Praze — Prague
- Semmelweis University — Budapest
- Petz Aladár Egyetemi Oktató Kórház — Győr
- Komárom-Esztergom Vármegyei Szent Borbála Kórház — Tatabánya
- InterHem — Bialystok
- Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne — Gdansk
- Pratia Onkologia Katowice — Katowice
New South Wales
- South West Radiology — Liverpool
- Slade Pharmacy — Mount Kuring-Gai
- Calvary Mater Newcastle — Waratah
North Carolina
- East Carolina University — Greenville
South Australia
- ICON Cancer Centre - Kurralta Park — Kurralta Park
Victoria
- The Alfred Hospital — Melbourne
Western Australia
- Royal Perth Hospital — Perth
Ontario
- Unity Health Toronto, St. Michael's Hospital — Toronto
Quebec
- McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05070845
The ClinicalTrials.gov registry entry for NCT05070845 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Primary Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention — of which PF-06835375 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05070845 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, New South Wales, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05070845 about?
NCT05070845 is a clinical study titled "Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia". This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP
What is the current status of trial NCT05070845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2022-02-02. Estimated completion is 2027-10-01.
What conditions does trial NCT05070845 study?
This clinical trial studies the following conditions: Primary Immune Thrombocytopenia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05070845?
The interventions under investigation include: PF-06835375 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05070845?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05070845 being conducted?
This trial has 20 study locations across North Carolina, New South Wales, South Australia, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.